PPARγ agonists can downregulate the Wnt/beta-catenin pathway, which is involved in inflammation, endothelial dysfunction, the proliferation of vascular smooth muscle cells, and vascular calcification, therefore PPARγ agonists might be therapeutic targets for the treatment of atherosclerosis [47]. This evidence concerns the gene CTNNB1 and atherosclerosis.